首页 | 本学科首页   官方微博 | 高级检索  
     

抗妇炎胶囊联合阿莫西林克拉维酸钾片对慢性盆腔炎患者炎性因子、血液流变学和子宫动脉血流动力参数的影响
引用本文:贺青文,杨 继,王建锋,任小苗,张 慧. 抗妇炎胶囊联合阿莫西林克拉维酸钾片对慢性盆腔炎患者炎性因子、血液流变学和子宫动脉血流动力参数的影响[J]. 现代生物医学进展, 2022, 0(22): 4380-4384
作者姓名:贺青文  杨 继  王建锋  任小苗  张 慧
作者单位:西安市人民医院(西安市第四医院)妇科 陕西 西安 710000
基金项目:西安市创新能力强基计划-医学研究项目(21YXYJ0048);陕西省科技厅自然基础研究项目(2018M7125)
摘    要:摘要 目的:观察抗妇炎胶囊联合阿莫西林克拉维酸钾片对慢性盆腔炎患者炎性因子、血液流变学和子宫动脉血流动力参数的影响。方法:采用随机数字表法将西安市人民医院2020年3月~2021年10月期间收治的慢性盆腔炎(n=112)患者分为对照组(阿莫西林克拉维酸钾片治疗,n=56)和研究组(抗妇炎胶囊联合阿莫西林克拉维酸钾片治疗,n=56),两组患者均治疗14d后,观察两组疗效、不良反应发生情况和临床症状缓解情况,对比两组治疗前、治疗14d后的炎性因子、血液流变学和子宫动脉血流动力参数变化情况。结果:研究组的临床总有效率高于对照组(P<0.05)。研究组的下腹疼痛、白带异常、腰骶骨疼痛、经期量多症状消失时间均短于对照组(P<0.05)。研究组治疗14d后血清单核细胞趋化蛋白1(MCP-1)、白介素-21(IL-21)、C反应蛋白(CRP)水平低于对照组,白介素-2(IL-2)水平高于对照组(P<0.05)。研究组治疗14 d后全血黏度低切、血浆黏度、全血黏度高切低于对照组(P<0.05)。研究组治疗14 d后阻力指数(RI)、搏动指数(PI)低于对照组,最大血流速度(Vmax)高于对照组(P<0.05)。两组不良反应发生率,组间对比无统计学差异(P>0.05)。结论:阿莫西林克拉维酸钾片联合抗妇炎胶囊治疗慢性盆腔炎,可降低炎性因子水平,改善血液流变学和子宫动脉血流动力参数,促进临床症状改善,效果显著。

关 键 词:抗妇炎胶囊;阿莫西林克拉维酸钾片;慢性盆腔炎;炎性因子;血液流变学;子宫动脉血流动力参数
收稿时间:2022-04-23
修稿时间:2022-05-18

Effects of Kangfuyan Capsule Combined with Amoxicillin Clavulanate Potassium Tablets on Inflammatory Factors, Hemorheology and Uterine Artery Hemodynamic Parameters in Patients with Chronic Pelvic Inflammatory Disease
Abstract:ABSTRACT Objective: To observe the effects of Kangfuyan capsule combined with amoxicillin clavulanate potassium tablets on inflammatory factors, hemorheology and uterine artery hemodynamic parameters in patients with chronic pelvic inflammatory disease. Methods: Using random number table method, patients with chronic pelvic inflammatory disease (n=112) who were admitted to Xi''an People''s Hospital from March 2020 to October 2021 were divided into control group (amoxicillin clavulanate potassium tablets treatment, n=56) and study group (Kangfuyan capsule combined with amoxicillin clavulanate potassium tablets treatment, n=56). After treatment for 14 days in both groups, the curative effect, the occurrence of adverse reactions and the relief of clinical symptoms of the two groups were observed, and the changes of inflammatory factors, hemorheology and uterine artery hemodynamic parameters before and 14d after treatment were compared between the two groups. Results: The total clinical effective rate of the study group was higher than that of the control group (P<0.05). The disappearance time of lower abdominal pain, abnormal leucorrhea, lumbosacral pain and multiple menstrual periods of the study group was shorter than that of the control group (P<0.05). 14 d after treatment, the levels of serum monocyte chemoattractant protein-1 (MCP-1), interleukin-21 (IL-21) and C-reactive protein (CRP) of the study group were lower than those of the control group, and the level of interleukin-2 (IL-2) was higher than that of the control group (P<0.05). 14d after treatment, the whole blood viscosity low shear, plasma viscosity and whole blood viscosity high shear of the study group were lower than those of the control group (P<0.05). 14d after treatment, the resistance index (RI) and pulsatility index (PI) of the study group were lower than those of the control group, and the maximum blood flow velocity (Vmax) was higher than that of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Amoxicillin clavulanate potassium tablets combined with Kangfuyan capsule can reduce the level of inflammatory factors, improve hemorheology and uterine artery hemodynamic parameters, and promote the improvement of clinical symptoms, which has a remarkable effect.
Keywords:Kangfuyan capsule   Amoxicillin clavulanate potassium tablets   Chronic pelvic inflammatory disease   Inflammatory factors   Hemorheology   Uterine artery hemodynamic parameters
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号